Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid Stoffw Microb

Langsenlehner, T; Langsenlehner, U; Renner, W; Kapp, KS; Krippl, P; Hofmann, G; Clar, H; Pummer, K; Mayer, R.
The Glu228Ala polymorphism in the ligand binding domain of death receptor 4 is associated with increased risk for prostate cancer metastases.
Prostate. 2008; 68(3):264-268 Doi: 10.1002/pros.20682
Web of Science PubMed FullText FullText_MUG Google Scholar


Führende Autor*innen der Med Uni Graz
Langsenlehner Tanja
Co-Autor*innen der Med Uni Graz
Clar Heimo
Hofmann Guenter
Kapp Karin S.
Langsenlehner Uwe
Mayer Ramona
Pummer Karl
Renner Wilfried

Dimensions Citations:

Plum Analytics:

Scite (citation analytics):

Death receptor 4, encoded by the TNFRSF10A gene, is an important mediator of apoptosis and its dysfunction may be related to cancer development and distant tumor spread. A single nucleotide polymorphism in TNFRSF10A (Glu228Ala, rs20576) within a conserved region of the extracellular cysteine-rich domain of death receptor 4 has been associated with an increased risk for a variety of tumor entities. Aim of the present study was to evaluate the role of the TNFRSF10A polymorphism in metastatic progression of prostate cancer after radiation therapy. We carried out a prospective study including 702 prostate cancer patients from the Austrian PROCAGENE (Prostate Cancer Genetics) study. Development of metastases was examined in regular follow-up investigations. TNFRSF10A genotypes were determined by a 5'-nuclease assay (TaqMan). Within a median follow-up time of 10 months (range 0-60 months), 24 (3.4%) patients developed metastases. In a Cox regression model including age at diagnosis and risk group as potential confounders, carriage of an 228Ala allele was associated with a relative risk of 2.47 (95% CI 1.10-5.54; P=0.028) for metastases. TNFRSF10A genotypes were not associated with tumor stage, grade, risk group or age at diagnosis. We conclude that the TNFRSF10A Glu228Ala polymorphism may be a novel independent risk factor for prostate cancer metastases after radiation therapy.
Find related publications in this database (using NLM MeSH Indexing)
Aged -
Aged -
Cohort Studies -
Cross-Sectional Studies -
DNA, Neoplasm - chemistry
DNA, Neoplasm - genetics
Genotype -
Humans -
Kaplan-Meier Estimate -
Ligands -
Male -
Neoplasm Metastasis -
Polymerase Chain Reaction -
Polymorphism, Single Nucleotide -
Proportional Hazards Models -
Prospective Studies -
Prostatic Neoplasms - genetics
Prostatic Neoplasms - pathology
Protein Structure, Tertiary -
Receptors, TNF-Related Apoptosis-Inducing Ligand -
Receptors, Tumor Necrosis Factor - genetics

Find related publications in this database (Keywords)
prostate cancer metastases
prognostic factors
death receptor 4
single nucleotide polymorphisms
© Med Uni Graz Impressum